UroGen Pharma (URGN) Misses Q4 EPS by 4c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $22.56 million.
GUIDANCE:
UroGen Pharma sees FY2024 revenue of $95-102 million, versus the consensus of $108.7 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransUnion (TRU) Tops Q3 EPS by 4c; Offers FY26 EPS Guidance
- Noble Corp (NE) Misses Q3 EPS by 81c; Offers Outlook
- Dorman Products (DORM) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
